CVS Health (CVS) Investor Day 2025 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2025 summary
3 Feb, 2026Strategic vision and business transformation
Committed to becoming America's most trusted healthcare company by simplifying care, improving access, affordability, and outcomes for 185 million people served, and transitioning to a consumer-focused health solutions business leveraging technology and digital solutions.
Executed a major leadership overhaul, exited non-core businesses, and invested $20 billion over 10 years in technology to enable growth and integration across business lines.
Established four growth pillars: best-in-class execution in core businesses, transforming consumer experiences, partnering with providers, and leveraging enterprise capabilities through technology.
Announced the launch of an Open Consumer Engagement Platform, aiming to commercialize technology assets and offer 'Engagement as a Service' to the industry by 2026, with active partner discussions.
Emphasized the unique reach of 9,000+ locations, 300,000 colleagues, and 85% of the U.S. population living within 10 miles of a facility.
Financial guidance and performance outlook
Raised 2025 guidance to at least $400 billion in revenue and $6.60–$6.70 adjusted EPS, with 2026 guidance of at least $400 billion in revenue and $7.00–$7.20 adjusted EPS.
Projects mid-teens adjusted EPS CAGR through 2028, driven by diversified businesses, Aetna margin recovery, specialty pharmacy growth, and improved healthcare delivery performance.
2026 adjusted operating income projected at $15.07–$15.41 billion, with all business segments contributing to growth.
Strong cash flow generation expected, with $55–$60 billion deployable cash from 2026 to 2028, prioritizing deleveraging, dividends, and future share repurchases.
Investments for the Open Engagement Platform are included in guidance, but upside from its commercialization is not yet reflected in long-term projections.
Business segment highlights and innovations
Aetna/Health Care Benefits achieved $2.5 billion AOI improvement in 2025, with further $1.7 billion targeted for 2026, focusing on operational excellence, technology, and new care models, and renewed focus on Medicare Advantage and Medicaid.
Healthcare delivery pivoted Oak Street Health from rapid expansion to margin improvement, expanded MinuteClinic primary care to 400+ locations, and enhanced Signify Health offerings.
Caremark retained 98% of customers, won $6 billion in new business, led in transparent pricing with TrueCost, and delivered $1.5 billion in client and member savings through biosimilars.
Specialty pharmacy remains the largest in the U.S., serving 2.2 million patients, leveraging AI and automation to reduce therapy start times by 45%.
Retail pharmacy reset earnings trajectory to at least flat, driven by cost discipline, technology, omnichannel expansion, and market share gains.
Latest events from CVS Health
- Integrated pharmacy, PBM, and digital platforms drive consumer-focused, affordable healthcare.CVS
Leerink Global Healthcare Conference 20269 Mar 2026 - 2025 revenue and EPS exceeded expectations, but earnings hit by goodwill and litigation charges.CVS
Q4 202510 Feb 2026 - Q2 revenue up 2.6% to $91.2B, but EPS and guidance cut amid Health Care Benefits headwinds.CVS
Q2 20242 Feb 2026 - Revenue up 6.3% to $95.4B, but large charges drove sharp earnings decline.CVS
Q3 202416 Jan 2026 - Leadership and pricing innovations set the stage for cautious but improving financial outlooks.CVS
Wolfe Research 2024 Healthcare Conference13 Jan 2026 - 2025 guidance targets EPS growth and revenue above $385B despite ongoing cost headwinds.CVS
Q4 20248 Jan 2026 - Q1 2025 revenue up 7% to $94.6B; adjusted EPS guidance raised to $6.00–$6.20.CVS
Q1 202520 Dec 2025 - 2024 saw robust financials, leadership transitions, and enhanced pay-for-performance alignment.CVS
Proxy Filing1 Dec 2025 - Key votes include board elections, auditor ratification, say-on-pay, and a shareholder rights proposal.CVS
Proxy Filing1 Dec 2025